Dennis Han Joon Kim

6879195, Apr 12, 2005

Jul 17, 2003

10/622627

Michael Green - Carlsbad CA, US
Nhat M. Nguyen - San Jose CA, US
Yohan Frans - Palo Alto CA, US
Dennis Kim - San Francisco CA, US
Todd Bystrom - Los Altos CA, US

Rambus, Inc. - Los Altos CA

H03L007/06

327147, 327156

A lock detection circuit operatively associated with a phase-locked loop indicates when a feedback clock signal is locked to a reference clock signal. The lock detection circuit counts the number of rising and falling edges of the feedback clock signal that are detected between rising edges of the reference clock cycle. The lock detection circuit counts the number of consecutive valid cycles of the reference clock signal during which a single rising edge and a single falling edge of the feedback clock signal are detected. Lock detection circuit asserts a lock signal when the number of consecutive valid cycles counted exceeds a predetermined number. Where the lock detection circuit indicates locked signals and then detects a reference clock cycle that is not valid, lock detection circuit continues to indicate lock if the next reference clock cycle is valid relative to a skewed feedback clock signal.

7084681, Aug 1, 2006

Mar 23, 2005

11/088152

Michael Green - Carlsbad CA, US
Nhat M. Nguyen - San Jose CA, US
Yohan Frans - Palo Alto CA, US
Dennis Kim - San Francisco CA, US
Todd Bystrom - Los Altos CA, US

Rambus Inc. - Los Altos CA

H03L 7/06

327147, 327156

A lock detection circuit operatively associated with a phase-locked loop indicates when a feedback clock signal is locked to a reference clock signal. The lock detection circuit counts the number of rising and falling edges of the feedback clock signal that are detected between rising edges of the reference clock cycle. The lock detection circuit counts the number of consecutive valid cycles of the reference clock signal during which a single rising edge and a single falling edge of the feedback clock signal are detected. Lock detection circuit uses a state machine to assert a lock signal when the number of consecutive valid cycles counted exceeds a predetermined number. Where the lock detection circuit indicates locked signals and then detects a reference clock cycle that is not valid, the lock detection circuit continues to indicate lock if the next reference clock cycle is valid relative to a skewed feedback clock signal.

8389472, Mar 5, 2013

Aug 21, 2006

12/063712

Alain D. Baron - San Diego CA, US
Dennis Kim - San Diego CA, US
David G. Maggs - San Diego CA, US
Matthew Wintle - San Diego CA, US

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

A61K 38/26
A61K 38/00
A61K 38/16
A61K 39/00

514 72, 514 74, 514 213, 4241851, 4241981, 530300, 530324

The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.

8501693, Aug 6, 2013

Aug 6, 2007

12/375734

Dennis Kim - La Jolla CA, US
Michael Trautmann - Hamburg, DE

Amylin Pharmaceuticals, LLC - San Diego CA
Astrazeneca Pharmaceuticals LP - Wilmington DE

A61K 38/36
A61K 38/00

514 136, 514 11, 514 72, 514 117

The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.

20090209469, Aug 20, 2009

Aug 6, 2007

12/374569

Dennis Kim - La Jolla CA, US
Michael Trautmann - Hamburg, DE
Don D. Johns - San Antonio IN, US
David Robbins - Weatherley Lake MO, US

A61K 38/17
A61K 38/22
A61P 9/00

514 12

The present invention relates to altering the concentration of various lipid molecules, specifically for example by shifting from small LDL particles to large LDL and HDL particles. The present invention also relates to methods for increasing average lipid particle size and methods for improving the cardiovascular risk profile of a subject by altering lipid particle sizes or concentrations or both.

20090210019, Aug 20, 2009

Feb 13, 2009

12/370984

Dennis Dong-Won Kim - La Jolla CA, US
Mark B. Knudson - Shoreview MN, US

A61N 1/36
A61M 37/00

607 3

A method and system for designing a therapy or for treating a condition associated with excess weight in a subject comprising applying a neural conduction block to the vagus nerve at a blocking site with the neural conduction block selected to at least partially block nerve impulses on the vagus nerve at the blocking site and administering a composition comprising an effective amount of an agent that alters the energy balance of the subject.

20210046313, Feb 18, 2021

Jul 27, 2020

16/939754

- St. Paul MN, US
Dennis Dong-won Kim - La Jolla CA, US
Mark B. Knudson - Shoreview MN, US
Katherine S. Tweden - Mahtomedi MN, US
Richard R. Wilson - Arden Hills MN, US

A61N 1/36
A61N 1/372
A61M 5/00
A61N 1/05

Various methods and apparatus for treating a condition associated with impaired glucose regulation in a subject comprising in one embodiment, applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses. In another embodiment, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to treat impaired glucose regulation. In other embodiments, up-regulation or down-regulation of various nerves, such as the vagus and its branches, and the splanchnic is used to modify the production of GLP-1 and GIP, thereby controlling glucose levels. In yet further embodiments, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to modify the production of GLP-1 and GIP, to treat impaired glucose regulation.

20190022393, Jan 24, 2019

May 21, 2018

15/984926

- St. Paul MN, US
Dennis Dong-won Kim - La Jolla CA, US
Mark B. Knudson - Shoreview MN, US
Katherine S. Tweden - Mahtomedi MN, US
Richard R. Wilson - Arden Hills MN, US

A61N 1/36
A61N 1/372
A61M 5/00
A61N 1/05

Various methods and apparatus for treating a condition associated with impaired glucose regulation in a subject comprising in one embodiment, applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses. In another embodiment, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to treat impaired glucose regulation. In other embodiments, up-regulation or down-regulation of various nerves, such as the vagus and its branches, and the splanchnic is used to modify the production of GLP-1 and GIP, thereby controlling glucose levels. In yet further embodiments, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to modify the production of GLP-1 and GIP, to treat impaired glucose regulation.